TG-4010 is an MVA vector-based vaccine of IL-2 and MUC-1 that induced an mOS of 19.3 mos among the 27 ccRCC patients in a phase II trial [104]. The gene discussed is MUC1; the disease is nonpapillary renal cell carcinoma.